Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over allegations that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL).
Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey held the initial case management conference for In re: Dupixent (dupilumab) Products Liability Litigation, MDL No. 3180, one year to the day after Weitz & Luxenberg and co-counsel filed the first Dupixent lawsuit.
“Sanofi’s own educational materials for doctors describe how this cancer can be mistaken for eczema and unmasked by Dupixent,” said Laura Baughman, the Weitz & Luxenberg partner leading the firm’s Dupixent litigation. “If the company understood that, the people taking this drug and the doctors prescribing it deserved a clear warning. The U.S. label still does not give one.”
CTCL is a rare cancer of the immune system that first appears on the skin. In its early stages it can look almost identical to eczema, the condition Dupixent is most often prescribed to treat. The lawsuits allege that Sanofi and Regeneron failed to warn patients and physicians about the risk of development or progression of CTCL with use of Dupixent. In March 2025, the FDA identified CTCL as a potential signal of serious risk associated with Dupixent based on its adverse event reporting system. A 2024 study published in the Journal of the American Academy of Dermatology found significantly higher odds of CTCL among eczema patients treated with Dupixent as compared to those not treated. Sanofi has said the scientific literature does not support a causal association.
“People were told their rash was eczema while a cancer progressed,” said Ellen Relkin, chair of Weitz & Luxenberg’s Drug and Medical Device Litigation practice group. “This litigation is about what the companies knew and when, and why patients never heard it.”
Patients should not stop taking any prescribed medication without talking to their doctor. People diagnosed with CTCL, mycosis fungoides or Sézary syndrome after using Dupixent can learn more at weitzlux.com or (917) LAWYERS.
About Weitz & Luxenberg:
For nearly four decades, Weitz & Luxenberg P.C. has represented people injured by negligence, recovering more than $26 billion in verdicts and settlements. Offices in New York, Cherry Hill, Los Angeles and Detroit.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261005152107/en/
Media gallery
